Reviva Pharmaceuticals Announces Conference Participation
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a company focused on advancing treatments for central nervous system and cardiometabolic diseases, has declared its involvement in the upcoming ROTH Healthcare Opportunities Conference. This event will feature a panel discussion highlighting the challenges and opportunities faced by smaller companies as they pursue wider market indications.
Conference Details and Schedule
Laxminarayan Bhat, Ph.D., the founder and CEO of Reviva, will lead this panel discussion, set to occur on a specified date in October. As a part of the conference, one-on-one investor meetings will also be available. These sessions aim to foster direct communication between Reviva's leadership and potential investors, providing insights into the company's vision and pipeline.
Reviva's Mission and Pipeline Overview
Renowned for its commitment to addressing unmet medical needs, Reviva is paving the way for the development of next-generation therapeutics. Currently, the company is concentrating on diseases affecting the central nervous system, inflammatory illnesses, and cardiovascular issues, thereby targeting critical health challenges.
Key Drug Candidates
Reviva's robust pipeline includes two promising candidates: brilaroxazine (RP5063) and RP1208. Both of these innovative therapies were discovered in-house and hold significant potential for advancing treatment in their respective areas. The company has secured composition of matter patents for both compounds, affirming its intellectual property rights across various global markets.
Reviva's Corporate Structure
Beyond its scientific pursuits, Reviva strives to cultivate strong relationships with investors and stakeholders. The corporate communication strategy is overseen by dedicated professionals ensuring transparency and engagement with the broader investment community.
How to Engage with Reviva
For those interested in learning more about Reviva and its initiatives, it is encouraged to connect with the company through their official website. Registration for the conference and arrangement for personal meetings with Reviva’s management can also be completed via their ROTH representative.
Frequently Asked Questions
What is the ROTH Healthcare Opportunities Conference?
The ROTH Healthcare Opportunities Conference is a forum for investors and pharmaceutical companies to discuss emerging trends and opportunities in healthcare and pharmaceuticals.
Who from Reviva is participating in the conference?
Laxminarayan Bhat, Ph.D., the CEO of Reviva Pharmaceuticals, is the key participant in the panel discussion at the conference.
What are Reviva's main focus areas?
Reviva’s research primarily addresses treatments for central nervous system disorders, inflammatory diseases, and cardiometabolic conditions.
What drugs does Reviva have in its pipeline?
Reviva is currently advancing two main drug candidates: brilaroxazine (RP5063) and RP1208, both of which are innovative therapies developed internally.
How can investors learn more about Reviva?
Investors can find more details about Reviva Pharmaceuticals and its drug pipeline by visiting the company’s official website or contacting investor relations.
